Literature DB >> 28885542

Correlation of the apparent diffusion coefficient and the standardized uptake value in neoplastic lesions: a meta-analysis.

Guohua Shen1, Huan Ma, Bin Liu, Pengwei Ren, Anren Kuang.   

Abstract

OBJECTIVE: Diffusion-weighted imaging and fluorine-18-fluorodeoxyglucose PET are increasingly being recognized as feasible oncological techniques. The apparent diffusion coefficient (ADC) measured by diffusion-weighted imaging and the standardized uptake value (SUV) from fluorine-18-fluorodeoxyglucose PET have similar clinical applications. The aim of this study was to assess the correlation between these two parameters in various cancers.
MATERIALS AND METHODS: Several major databases were searched for eligible studies. The correlation coefficient (ρ) values were pooled in a random-effects model. Begg's test was used to analyze the existence of publication bias and the sources of heterogeneity were explored in subgroup analyses on the basis of study design, diagnostic method, scanning modality, and tumor type.
RESULTS: Thirty-five articles were accepted. The pooled ρ value of all of the accepted studies was -0.30 (95% confidence interval: -0.33 to -0.27), and notable heterogeneity was present (I=69.4%, P<0.001), which indicated a relatively weak negative correlation. The pooled ρ values were -0.26, -0.33, -0.32, and -0.33 for the SUVmax/ADCmean, SUVmax/ADCmin, SUVmean/ADCmean, and SUVmean/ADCmin relationships, respectively. The study design and diagnostic method were potential sources of heterogeneity. Lung cancer showed a stronger correlation (ρ=-0.42) than head and neck cancer (ρ=-0.27), cervical cancer (ρ=-0.21), and breast cancer (ρ=-0.23). A Begg's test indicated no significant publication bias among the accepted studies (P>0.05).
CONCLUSION: The two functional parameters of ADC and SUV showed a very weak inverse correlation, which may contribute toward a sophisticated characterization of tumor biology. However, the findings require further validation with trials with large samples and different tumor types.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28885542     DOI: 10.1097/MNM.0000000000000746

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  5 in total

1.  Multiparametric PET/MR imaging biomarkers are associated with overall survival in patients with pancreatic cancer.

Authors:  Bang-Bin Chen; Yu-Wen Tien; Ming-Chu Chang; Mei-Fang Cheng; Yu-Ting Chang; Shih-Hung Yang; Chih-Horng Wu; Ting-Chun Kuo; I-Lun Shih; Ruoh-Fang Yen; Tiffany Ting-Fang Shih
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-23       Impact factor: 9.236

2.  Cervical Cancer: Associations between Metabolic Parameters and Whole Lesion Histogram Analysis Derived from Simultaneous 18F-FDG-PET/MRI.

Authors:  Hans-Jonas Meyer; Sandra Purz; Osama Sabri; Alexey Surov
Journal:  Contrast Media Mol Imaging       Date:  2018-07-30       Impact factor: 3.161

3.  Relationships between histogram analysis of ADC values and complex 18F-FDG-PET parameters in head and neck squamous cell carcinoma.

Authors:  Hans-Jonas Meyer; Sandra Purz; Osama Sabri; Alexey Surov
Journal:  PLoS One       Date:  2018-09-06       Impact factor: 3.240

4.  Spatial relationship of 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography and magnetic resonance diffusion imaging metrics in cervical cancer.

Authors:  John M Floberg; Kathryn J Fowler; Dominique Fuser; Todd A DeWees; Farrokh Dehdashti; Barry A Siegel; Richard L Wahl; Julie K Schwarz; Perry W Grigsby
Journal:  EJNMMI Res       Date:  2018-06-15       Impact factor: 3.138

5.  Correlation between histogram-based DCE-MRI parameters and 18F-FDG PET values in oropharyngeal squamous cell carcinoma: Evaluation in primary tumors and metastatic nodes.

Authors:  Antonello Vidiri; Emma Gangemi; Emanuela Ruberto; Rosella Pasqualoni; Rosa Sciuto; Giuseppe Sanguineti; Alessia Farneti; Maria Benevolo; Francesca Rollo; Francesca Sperati; Filomena Spasiano; Raul Pellini; Simona Marzi
Journal:  PLoS One       Date:  2020-03-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.